LKFT — Lakefront Biotherapeutics NV Share News
0.000.00%
Last trade - 00:00- €1.69bn
- -€1.28bn
- €1.11bn
Galapagos NV reports results for the quarter ended June 30 - Earnings Summary
Brief: Galapagos H1 Revenue EUR 140.3 Million
Brief: Galapagos Appoints Aaron Cox As CFO
Brief: Galapagos presented new data at ICML 2025 from Cohort 3 of ATALANTA-1 in relapsed/refractory indolent NHL patients
Galapagos jumps after it walks back on spinoff, appoints new CEO
Brief: Galapagos Announces Strategic Update On Proposed Separation, Leadership Transition, Board Changes
Pharma group Galapagos picks new CEO, backtracks on spinoff
Galapagos NV reports results for the quarter ended March 31 - Earnings Summary
Brief: Galapagos Announces Executive Leadership Updates
Brief: Galapagos CFO, COO Thad Huston To Leave Company on August 1
Brief: Euronext Says Montea To Be Included In BEL20 Indice From March 24
Galapagos fall as MS downgrades to "underweight", cuts PT
Galapagos NV reports results for the quarter ended December 31 - Earnings Summary
Brief: Galapagos NV Says FY Operating Loss EUR 188.3 Million
Europe Research Roundup: Anglo American , Energean, Savills
Galapagos downgraded to 'underweight', as Barclays deems shares 'boxed in'
Barclays cautious on European pharma in H1, sees re-rating chance in H2
U.S. STOCKS ON THE MOVE-Galapagos, Tapestry, Autodesk
Galapagos to spin off innovative medicines business (updated)